Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: A post hoc pooled analysis of two clinical studies
Risk Management and Healthcare Policy Aug 10, 2017
Bell KF, et al. – Researchers carried out a pooled analysis of data from these two studies to evaluate the impact of dapagliflozin 5 or 10 mg/d plus metformin XR (combination therapy) compared with placebo plus metformin XR (metformin monotherapy) on diabetes quality measures. The data validated that initial combination therapy with dapagliflozin 5 or 10 mg/d and metformin enhanced quality measures relevant to clinical outcomes and diabetes care.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
